Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Candida albicans and other pathogenic vaginal microbes refers to a diverse group of microorganisms, including fungi, bacteria, and protozoa, that cause infections of the female lower reproductive tract. Candida albicans is the most common cause of vulvovaginal candidiasis (VVC), characterized by its ability to transition from a commensal yeast to an invasive hyphal form [1]. Other significant pathogens in this category include Gardnerella vaginalis and various anaerobes associated with bacterial vaginosis (BV), as well as the protozoan Trichomonas vaginalis [2]. These microbes typically cause disease by displacing protective Lactobacillus species, leading to a state of dysbiosis and inflammation [3]. Treatment involves a variety of antimicrobial agents, such as azoles for fungal infections and nitroimidazoles for bacterial or protozoal infections, which target specific metabolic or structural components of the pathogens [4]. Clinical management is often complicated by the formation of biofilms and the increasing prevalence of drug-resistant strains [5].
Antifungal agents like azoles inhibit the enzyme lanosterol 14-alpha-demethylase, preventing ergosterol synthesis and disrupting fungal cell membrane integrity [4]. Antibacterial and antiprotozoal agents like nitroimidazoles are reduced within the pathogen to form reactive intermediates that cause DNA strand breakage [2]. Polyene antifungals bind directly to ergosterol in the cell membrane, creating pores that lead to leakage of intracellular contents [1].
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Candida albicans and other pathogenic vaginal microbes.